Review

Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis

Márk Félix Juhász,1,2 Orsolya Varannai3,4, Dávid Németh,5 Zsolt Szakács3,4, Szabolcs Kiss3,4, Vera Dóra Izsák3,4, Ágnes Rita Martonosi4, Péter Hegyi3,4, Andrea Párniczky2,4

1 Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
2 Heim Pál National Pediatric Institute, Budapest, Hungary
3 Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary
4 János Szentágothai Research Center, University of Pécs, Pécs, Hungary

1. Introduction

Cystic fibrosis (CF) (OMIM: #219700), is a hereditary disease caused by mutations in both alleles of the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on the long arms of chromosome 7. It is one of the most common autosomal recessive disorders, affecting approximately 1 out of every 3,000 live-born worldwide [1]. Mutations – more than 2,000 documented to date, divided into six classes – generally result in the absence or the reduced/annulled function of the CFTR-protein, a transmembrane Cl−-channel present in the apical surface of epithelial cells throughout the body. The defect of this channel causes the damage of multiple organs, mainly: the airways, pancreas, gastrointestinal (GI) tract, liver and reproductive system [2].

In the pancreatic and biliary ducts, the defective CFTR-channels will result in thickened secretion production, chronic obstruction of these ducts, leading to chronic pancreatitis and exocrine insufficiency. Loss of exocrine function will lead to fat malabsorption and the deficiency of fat-soluble vitamins, including vitamin D [2–4]. Nutritional status and the level a micro- and macronutrients have a strong association with lung function and greatly determine the morbidity and mortality of CF patients [5].

Vitamin D is crucial for bone health: mainly stimulating the calcium (Ca) absorption from the gut, its deficiency can lead to secondary hyperparathyroidism and bone loss [6]. Vitamin D also affects nearly all cells of both the innate (monocytes, macrophages, dendritic cells, etc.) and the adaptive (B- and T-cells) immune system, with sufficient vitamin D levels decreasing the risk of respiratory infections, thus possibly delaying CF progression and mortality [5,7]. As of 2019, the Cystic Fibrosis Foundation recommends different, consensus-based doses of cholecalciferol (D3) rather than ergocalciferol (D2) in different age groups of CF patients to be administered as a single dose.

Abstract

Despite routine supplementation, vitamin D insufficiency is often seen in cystic fibrosis (CF) patients on account of pancreatic insufficiency. Vitamin D is a crucial component of bone health and affects nearly all cells of the immune system. However, clinical benefits or harms associated with supplementation are poorly documented. In this systematic review, we included randomized controlled trials (RCTs) that compared vitamin D supplementation with placebo (i.e. 'non-increased dose') in CF patients. Analysing the 8 included RCTs, the intervention group had significantly higher serum 25-hydroxyvitamin D (se25OHD) levels, but there were no significant differences found in the quantitative synthesis of clinical outcomes, including bone disease-, respiratory status- and immunological status-related outcomes. Based on our current results, while a higher vitamin D dose elevates se25OHD, it does not seem to influence clinical outcomes. Future RCTs should include outcomes of past studies and apply longer follow-up periods to document long-term patient-important outcomes.

© 2020 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)}
evated when necessary, with the goal of reaching a serum 25-
hydroxyvitamin D (25(OH)D) concentration of at least 30 ng/ml
(75 nmol/l) [8]. However, clinical benefits and harms of vitamin
d supplementation in this population are poorly documented. The
last systematic review of controlled trials was conducted in 2014
[9] with only three of the included randomized controlled trials
(RCTs) supplying useful information and with inconclusive results
on account of the heterogeneity and small sample size of the RCTs.

As more RCTs have been published since, our aim was to re-
evaluate the clinical benefits and possible adverse events accom-
panying a higher vitamin D dose in CF patients by conducting a
systematic review and meta-analysis of RCTs in the topic.

2. Methods

2.1. Protocol and registration, reporting

This meta-analysis was registered with PROSPERO under regis-
tration number CRD42020155847. There have been no deviations
from the registered protocol. We adhered to the recommendations
of the ‘Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA)’-group in reporting our findings and writing the
review [10].

2.2. Eligibility criteria

Only randomized controlled trials were considered eligible for
inclusion in this systematic review. We determined eligibility
based on the PICO of trials in the following manner:

P - Population: We included studies that examined CF patients,
either paediatric or adult or both. There were no other restrictions
based on the examined participants of these trials – exacerbation
and stable disease were both allowed, also comorbidities and sub-
populations of CF patients with the intent of conducting post-hoc
analyses if feasible and necessary. Trials where only an examined
subpopulation of participants have CF were also allowed; however,
at the end, no such trials were eligible for inclusion.

I – Intervention: We included studies that, as an intervention,
supplemented vitamin D to the participants in any dose, any form
(vitamin D3 or D2) and for any duration. Compounds consisting of
multiple active substances including vitamin D were also allowed.
Studies utilizing sunshine as a means of vitamin D supplemen-
tation were not eligible for inclusion.

C – Comparator: Placebo or if the intervention in given study
consisted of a compound with multiple active substances including
vitamin D, any otherwise identical therapy lacking vitamin D.

Continued or basal vitamin D supplementation was allowed if
it did not categorically differ between the intervention and com-
parator groups.

O – Outcome: There were no restrictions applied based on ex-
amined outcomes in the individual studies. Our primary interests
were as entailed by our PICO: Bone mineral density and other
quantifiable bone disease-related outcomes; mortality; height and
weight Z-score; 25(OH)D, Ca, and parathyroid hormone (PTH) con-
centrations; respiratory status (forced expiratory volume in the
first second (FEV1), forced vital capacity (FVC), forced expiratory
flow at 25% of FVC (FEF25%), other assessed respiratory para-
eters); measures of immunological status (immunological markers,
exacerbation due to infection, antibiotic use); quality of life; ad-
verse events. Apart from these, all other examined outcomes were
considered valuable and if a study failed to report on any of the
listed outcomes it was still not to be excluded from our systematic
review.

Studies were not restricted in eligibility based on length of
follow-up.

2.3. Systematic search and selection

We conducted the systematic search – using the same search
key as detailed in supplementary material Suppl1. - in 4 databases:
Embase, MEDLINE (via PubMed), Cochrane Central Register of Con-
trolled Trials (CENTRAL) and Web of Science. The date of last sys-
tematic search was 9th October 2019. There were no restrictions
imposed on the search. Citations were exported as a shared pool to
a citation manager software, EndNote X9 (Clarivate Analytics). Two
independent reviewers (MF and OV) conducted the selection by
title, abstract and full-text based on the previously disclosed pre-
determined set of rules. After selecting by title and abstract – in
an inclusive manner -, the rate of agreement was determined and
documented by calculating the Cohen’s kappa coefficient (κ) and
the two citation pools were merged before screening by full text.
Any disagreements were settled by an independent third party
(YS). Exclusions made in the full text phase of selection were doc-
umented, studies of the same population were linked together.
In case of population overlaps for an outcome, the article with the
higher number of participants was preferred.

Citations of the studies inspected for eligibility in the full-text
phase were reviewed in order to identify any additional eligible
trials.

2.4. Data extraction

Information on data extraction is available in the supplemen-
tary material.

2.5. Risk of bias assessment

The Revised Risk of Bias Assessment Tool (RoB 2) [11] was used to
assess the risk of bias in the individual studies (all RCTs). MF
and OV independently conducted the assessment, final results are
based on consensus. Assessments were made on a study level but
the nature of the examined outcomes were consistent – mostly re-
results of laboratory examinations at predetermined points in time.
Results of the risk of bias assessment are available in the supple-
mentary material.

2.6. Statistical analysis

All statistical analyses in this study were carried out using
Stata 15 SE (StataCorp). Pooled weighted mean difference (WMD)
or standardized mean difference (SMD) were calculated with 95%
confidence intervals (CI) for continuous outcomes. A random ef-
fects model was applied for all analyses, with the DerSimonien-
Laird estimation. Statistical heterogeneity was analysed using the
I² statistic and the chi-square to gain probability-values; I² rep-
resents the magnitude of the heterogeneity (moderate: 30–60%, sub-
stantial: 50–90%, considerable: 75–100%) [12].

2.7. Determination of quality of evidence

Recommendations of the ‘Grading of Recommendations As-
sumption, Development and Evaluation’ (GRADE) working group
[13] were followed upon assessing the quality of the evidence (MF
and VI, independently). The GRADEpro Guideline Development Tool
[14] was used for preparing the Summary of Findings table and ac-
cessory tables.

3. Results

3.1. Systematic search and selection

The systematic search yielded 2,738 hits, 1,011 after duplicate
removal. These 1,011 records were screened. 931 studies were ex-
Fig. 1. PRISMA flow diagram indicating the number of studies identified, screened and excluded as well as the number of eligible studies [10].

included based on title and abstract (Cohen’s kappa: 0.86), leaving 80 studies to be assessed based on reviewing the full text. Out of the 80 articles, 72 were excluded, mostly because the full-text revealed that they did not contain original data or that they were alternative reports / conference abstracts of identical / overlapping study populations. At the end, 8 articles remained of which 2 were conference abstracts not providing useful data for the quantitative synthesis but that could be included in the systematic review (Fig. 1).

3.2. Study characteristics

The main characteristics of included studies are gathered in Table 1.

3.3.1. Primary outcomes

3.3.1.1. Bone mineral density and other quantifiable bone disease-related outcomes. Only 2 of the included studies (Haworth 2004, Hillman 2008) reported on bone health-related outcome measures. Fig. 2 presents the quantitative synthesis of intervention effects on serum bone alkaline phosphatase (BALP), serum osteocalcin and lumbar spine Z-score – these were the only three parameters that were consistently measured in both studies – with no significant difference between groups neither in the individual studies, nor overall. It is to be noted that Hillman 2008 examined children while Haworth 2004 examined adults. Hillman 2008 also assessed BMC, BMD and Z-score in: whole body, lumbar spine, 1/3 radius and hip – with no significant differences between groups. Haworth 2004 also assessed total hip and distal forearm Z-scores with no significant differences between groups.

3.3.1.2. Mortality. The 2 studies examining adult CF patients admitted with pulmonary exacerbation (Grossman 2012, Tangpricha 2019) provided data on mortality. During the 12-month follow-up 6 out of 30 patients died (1 intervention, 5 placebo; p=0.03) in Grossman 2012 and 3 out of 91 patients died (3 intervention, 0 placebo) in Tangpricha 2019. The other 6 studies examining clini-
### Table 1
Characteristics of included studies. RCT= randomized controlled trial, se25OHD= serum 25-hydroxyvitamin D, IU= international units, SD= standard deviation, med= median, IQR= interquartile range, FEV1= forced expiratory volume in the first second, FVC= forced vital capacity, FEF25%= forced expiratory flow at 25% of FVC, Ca= serum calcium, PTH= serum parathyroid hormone, NA= not available. *= only patients with se25OHD <30 ng/ml were accepted.3.3. Synthesis of results.

| Author year | Country | Centres, blinding, design | full-text | N° of patients | Study length | Age (years) | se25OHD (ng/ml) | other descriptors | Population at baseline | Interventions, dose of vitamin D (IU) | Comparator | List of examined outcomes |
|-------------|---------|---------------------------|-----------|----------------|--------------|-------------|----------------|---------------------|------------------------|--------------------------------------|------------|--------------------------|
| Tangpricha 2019 [15] | USA | multicentre, quadruple-blind RCT | yes | 91 | 12 months | mean±SD 28.8±7.9 | 27.0±10.9 | pulmonary exacerbation; 93.4% pancreatic insufficient, 33% CFDRD | | 1 × 250,000 IU within 1st 72 h, 50,000/2 weeks D3 starting month 3 | placebo, 800-2,000 IU/day | se25OHD FEV1, Ca, creatinine, albumin, LL-37, return to baseline FEV1 |
| Pincikova 2017 [16,17] | Sweden | single-centre, unblinded RCT | yes | 16 | 5 months | med (IQR): 19 (12;32) | 22.87±9.64* | 62.5% ≥18 years old, 87.5% pancreatic insufficient, 18.8% mild CF phenotype (at least one class IV or V mutation), 31.3% receiving azithromycin treatment, FEV1% of predicted (mean±SD): 72.7±30.9 | | 35,000 or 50,000 IU / week (<or≥16 years) D2 or D3 | “continued vitamin D” (dose not stated) | humoral and cellular immunity, se25OHD, FVC, FEF25%, |
| Kanhera 2017 [18] | USA | single-centre, double-blind RCT | yes | 23 | 12 weeks | mean±SD 32±11 (D3), 34±10 (placebo) | 25±5 (intervention) - 22±6 (placebo) * | 100% pancreatic insufficient, 20% CFDRD | | 50,000 IU /week D3, basal (mean±SD): 1,100±849 IU /day | placebo, basal: 1,770±1643 IU /day | se25OHD, gut and airway microbiota |
| Grossman 2012 [19,20] | USA | single-centre, double-blind RCT | yes | 30 | 12 months | med (range): D3: 24.9 (16.01), placebo: 28.2 (30.89) | 30.6±3.2 (intervention) - 28.7±3.5 (placebo) | pulmonary exacerbation; 93.3% pancreatic insufficient, 50% CFDRD, 53.3% DF508 homozygous, 23.3% DF508 hetero, 23.3% unknown mutation | | 1 × 250,000 IU D3 within 48 h, basal: (mean range): (2,600) IU/day | placebo, basal: (mean range): (400, 2,800) IU/day | se25OHD, PTH, humoral immunity, return to baseline FEV1 |
| Hillman 2008 [21] | USA | single-centre, double-blind crossover RCT | yes | 12 | 9 months /arm | mean±SD 9.1±2.3 | 35.4±13.2 | all patients taking pancreatic enzymes, Ca intake (mean±SD): 861±390 mg /day, lumbar spine Z-score (mean±SD): -0.97±0.87 | | 11: 1,600 IU /day D3; 12: 1g/day Ca; 13: 1,600 IU D3 + 1g Ca /day; 14: placebo. Basal vitamin D: 400 IU /day | se25OHD, PTH, bone metabolism markers, albumin, Ca | se25OHD, PTH, bone metabolism markers, |
| Haworth 2004 [22] | UK | single-centre, double-blind RCT | yes | 30 | 12 months | mean±SD 29.4±7.8 (D3), 25.9±8.0 (placebo) | 24.4±10.2 (intervention) - 21.6±10.8 (placebo) NA* | lumbar spine Z score ≥-1, 100% pancreatic insufficient, 8 patients in each group received oral corticosteroids | | 2 × 800 IU D3 + 1g Ca /day; basal: 900 IU/day | placebo, basal: 900 IU/day | se25OHD, PTH, bone metabolism markers, |
| Manshadi 2012 [23] | Canada | single-centre, double-blind RCT interim | no | 40 | 3 months | mean±SD 34.4±1.4 | 23.3% diabetes, 32.4% homozygous delta F, 64.9% Pseudomonas aeruginosa positive, BMI 22.7±3.4 kg/m2, FEV1 2.3 ± 1.1 l | | 5,000 IU/day D3, basal: yes, dose not stated | placebo, basal: yes, dose not stated | se25OHD |
| Brown 2006 [24] | USA | double-blind RCT (N° of centres unknown) | no | 59 | 24 months | mean±SD 12.1±3.1 | NA | 10 or 20 IU/kg/day calcitriol, (<or≥45kg): basal: usual vitamin D, dose not stated + Ca 500 mg /day | | placebo, basal: usual vitamin D, dose not stated + Ca 500 mg /day | bone metabolism markers, pubertal stage |
cally stable CF patients did not report on any cases of mortality. In the case of Haworth 2004, Pincikova 2017 and Kanhere 2017 drop-outs, missing outcome data and adverse events were thoroughly reported, allowing us to reasonably assume 0 deaths in these studies. In Brown 2006, Hillman 2008 and Manshadi 2012 reporting in these fields were lacking.

3.3.2. Secondary outcomes

3.3.2.1. Serum total 25-hydroxyvitamin D (25OHD) concentration.

Fig. 3 shows the comparison of continuous vitamin D supplementation versus placebo regarding 25OHD concentration, with significantly higher levels with treatment (WMD: +10.48 ng/ml; 95%CI: [+0.72; +20.24]; I²=89.7%). Haworth 2004 only provided data on change in 25OHD, Grossman 2012 only applied a single dose of vitamin D supplementation thus they were not included in this quantitative synthesis. We decided to include the 12-month outcomes from Tangpricha 2019 despite them starting with a single dose of vitamin D, as they initiated continuous supplementation at the 3-month visit. Manshadi 2012 only provided data for the vitamin D group, Brown 2006 only provided baseline data, thus they could not be included.

3.3.2.2. Respiratory status-related outcome measures. The two studies examining pulmonary exacerbation (Grossman 2012, Tangpricha 2019) reported on return to baseline FEV1% (patients whose FEV1% of predicted returned to within 95% of baseline i.e. the best lung function in the 6 months / 1 year before the study) but in different subgroups of patients, thus results were not pooled. Grossman 2012 analysed patients whose FEV1% of predicted decreased greater than 10% from baseline to admission – 90 vs 50% returned to baseline in the vitamin D vs placebo groups, respectively (p=0.12). Tangpricha 2019 reported 35.3% of vitamin D and 25.3% of placebo patients returning to baseline at month 3, among all patients.

Tangpricha 2019 also reported on mean FEV1% (no significant differences between groups), Pincikova 2017 on FVC (significantly increased in D3 group compared to baseline) and FEF25% (no significant differences).

3.3.2.3. Adverse events. Adverse events reported by the individual studies are gathered in Table 2.

3.3.3. Additional outcomes

All outcomes pre-planned in our protocol and outcomes reported on by multiple studies were assessed. Pooled analysis was possible in the case of serum Ca, PTH, cathelicidin (LL-37) and albumin, without significant differences between groups. These outcomes are available in the supplementary material.

3.4. Quality of evidence

We included seven outcomes in our main Summary of Findings table: long-term survival (not reported), 12-month mortality after exacerbation (not pooled, opposing results, very low certainty), return to baseline lung function after exacerbation (not pooled, favoured vitamin D, very low certainty), adverse event rate (not pooled, no difference, very low certainty), quality of life (not reported), lumbar spine Z-score (no significant difference, very low certainty) and 25OHD (significantly higher in intervention group, moderate certainty). The main Summary of Findings table, and the one of additional outcomes are available in the supplementary material.
4. Discussion

The meta-analysis of the included RCTs demonstrated significantly higher se25OHD levels in the intervention group and no significant differences between intervention and comparator – neither on a study-level nor in total – regarding: lumbar spine Z-score, serum levels of BALP, osteocalcin, Ca, PTH, LL-37 and albumin. All of the included studies applied a basal vitamin D dose, meaning that only the comparison of this basal to a higher vitamin D dose could serve as a means to evaluate the intervention.

Even though the number of RCTs in the field of interest has doubled since the last systematic review, the lack of significant dif-

Fig. 3. Forest-plot showing the comparison of vitamin D versus placebo regarding the effect on serum total 25-hydroxyvitamin D concentration (ng/ml) in studies using continuous supplementation. N=number, SD=standard deviation, WMD=weighted mean difference, CI=confidence interval.

Table 2

| Study identifier     | Adverse events intervention group | Adverse events control group |
|----------------------|-----------------------------------|------------------------------|
| Tangpricha 2019      | n=32; 11 renal adverse events (1 nephrolithiasis, 2 elevated creatinine, 3 polydipsia, 5 polyuria), 0 gastrointestinal, 4 neurologic (1 fatigue, 3 increased confusion), 11 pulmonary (1 cough, 2 chest pain, 2 decreased lung function, 1 dyspnea, 1 hemoptysis, 2 increased sputum, 2 upper respiratory tract infection), 6 other | n=33; 3 renal adverse events (2 polydipsia, 1 polyuria), 2 gastrointestinal (1 diarrhea, 1 nausea), 5 neurologic (3 fatigue, 1 headaches, 1 increased confusion), 14 pulmonary (4 cough, 2 decreased lung function, 2 dyspnea, 2 hemoptysis, 2 increased sputum, 2 upper respiratory tract infection), 9 other |
| Kanhere 2017         | “There were no clinical signs of hypercalcaemia and no reported symptoms of vitamin D toxicity, as assessed by patient questionnaire at the final study visit.” |                                                                                 |
| Grossman 2012        | “There were no reported symptoms of vitamin D toxicity as assessed by patient questionnaire at any study visit, no clinical signs of hypercalcaemia, no significant changes in mean serum calcium or PTH concentrations.” |                                                                                 |
| Haworth 2004         | “The patients did not report any significant adverse events with drug or placebo, and there were no documented episodes of hypercalcaemia.” |                                                                                 |
| Manshadi 2012        | “No adverse events were identified during the study period.” |                                                                                 |
| Brown 2006           | nephrolithiasis (n=1), asymptomatic hypercalcaemia (n=1) | nephrolithiasis (n=1), persistent hypercalciuria (n=2) |
| Pincikova 2017       | No reports on presence / absence of adverse events. |                                                                                 |
| Hillman 2008         | No reports on presence / absence of adverse events. |                                                                                 |
ferences between groups should still not be considered as definite ineffectiveness, the quality of evidence being very low. The main reason behind this is the low number of participants in each study and the heterogeneous choice of reported outcomes resulting, in most cases, less than 100 participants per comparison.

However, the tendency of our current results suggests that an increased vitamin D dose (usually an additional 1,600-5,000 IU/day in the included studies) when compared with placebo plus the patients’ continued, basal vitamin D dose (usually 400-1,800 IU/day, which is roughly equivalent to the initial regimen recommended by the CF Foundation (Table 3)) while significantly raises se25OHD, does not influence clinical or other laboratory outcome measures.

Based on our results, it seems that a higher dose is unnecessary, as it poses no additional benefits. But it is also of note that, while only three of the RCTs excluded patients with se25OHD ≥30 ng/ml, six studies experienced baseline mean se25OHD <30 ng/ml, which is the target minimum se25OHD value recommended by the CF Foundation. This value, in contrast with the >20 ng/ml recommendation for the general population [27,28], was modelled after endocrinology and osteoporosis guidelines given the frequent vitamin D deficiency, lower bone density and bone health markers, and higher rate of fractures among CF patients [29,30]. Accordingly, similar target se25OHD levels are recommended by European (≥30 ng/mL) and Australasian (≥20 ng/mL) end of winter, ≥24-28 ng/mL rest of the year) CF Societies [25,26]. It seems that the recommended initial dose is often inadequate for achieving the target se25OHD, thus, even though we observed no clinical benefits, we think it would be sensible to consider a higher initial vitamin D dose for CF patients – more in line with the European recommendations, or the second dose step of the CF Foundation. A higher vitamin D dose, as described by the individual studies, was also not accompanied by a higher rate of adverse events (Table 2).

We would also like to call on future RCTs of vitamin D therapy in CF to include outcomes of preceding studies, enabling the rise of high-quality scientific evidence.

4.1. Strengths and limitations

This is the largest systematic review to date to examine vitamin D supplementation in CF. To our knowledge, this is the first review to include only RCTs, in order to analyse only the highest quality clinical trials. We were able to identify 8 RCTs, of which 6 supplied useful information for meta-analyses – 3 more than in the last systematic review.

Our study has several limitations. First of all, while more RCTs emerged since the last meta-analysis, the choice of outcomes, in most cases, did not overlap. While we understand the importance of presenting novel results, we highly recommend including outcomes of past studies in order to achieve high quality scientific evidence. Partly because of this, and partly because of the low participant number in the studies themselves, high risk of imprecision was noted, all comparisons were well below the optimal information size. Indirectness was also present as all studies applied a basal vitamin D dose. The research question at hand should have been vitamin D versus no vitamin D, which of course, would be unethical in such a high-risk population. We would also like to point out that due to the short follow-up periods, long-term patient-important outcomes, such as mortality and exacerbations, are yet to be documented. While the mean age in most studies was between 20 and 35 years, Hillman 2008 examined a younger (mean age: 9.1 years) population. Also, this was a crossover study, while others applied a parallel design.

4.2. Implications...

... for practice: Additional vitamin D does not seem to influence clinical and laboratory outcomes. However, CF patients receiving vitamin D, especially those receiving their initial dose, should be closely monitored as insufficient is frequent.

... for research: Outcomes of past studies should be included. RCTs with longer follow-up periods (5 years or more) should also be conducted to observe the long-term effects of supplementation.

Authors’ contributions

MFJ wrote the manuscript and took part in the selection and data extraction process. OV, ÁM, VI took part in the selection and extraction process, and contributed to the manuscript. DN conducted the statistical analysis of the data. ZS and SK provided methodological guidance. AP and PH contributed to and supervised the writing of the manuscript and gave medical insight. All authors have (1) contributed to the concept of the study; (2) re-

| Table 3 |
|---|
| 2012 CF Foundation Vitamin D guidelines (reapproved in 2019) |
| Age group | Target se25OHD | Initial dose (IU/day) | Strength of recommendation |
|---|---|---|---|
| ~1 year | ≥30 ng/ml | 400-500 | 2nd step |
| 1-10 years | ≥30 ng/ml | 800-1,000 | 3rd step |
| >-10 years | ≥30 ng/ml | 800-2,000 | 4th step |

| 2013 European Cystic Fibrosis Society recommendations (republished in 2019) |
|---|---|---|---|
| Age group | Target se25OHD | Initial dose (IU/day) | Strength of recommendation |
|---|---|---|---|
| <1 year | ≥30 ng/ml | 1,000-2,000 | Insufficient evidence, consensus recommendation |
| >1 year | ≥30 ng/ml | 1,000-5,000 | Insufficient evidence, consensus recommendation |

| 2017 Thoracic Society of Australia and New Zealand recommendations (republished in 2020) |
|---|---|---|---|
| Age group | Target se25OHD | Initial dose (IU/day) | Strength of recommendation |
|---|---|---|---|
| Infants | ≥20 ng/ml end of winter; ≥24-28 ng/mL rest of the year | Base supplementation on above US and EU recommendations | Insufficient evidence, consensus recommendation |

---

MFJ wrote the manuscript and took part in the selection and data extraction process. OV, ÁM, VI took part in the selection and extraction process, and contributed to the manuscript. DN conducted the statistical analysis of the data. ZS and SK provided methodological guidance. AP and PH contributed to and supervised the writing of the manuscript and gave medical insight. All authors have (1) contributed to the concept of the study; (2) re-
vised the manuscript; (3) read and approved the final version of the manuscript.

Funding

This work was supported by the Human Resources Development Operational Programme Grant [grant number: EFOP-3.6.2-16-2017-00006 – LIVE LONGER], co-financed by the European Union (European Regional Development Fund) within the framework of Programme Széchenyi 2020. AP received a Strategic Research Centre Award from the Cystic Fibrosis Trust [grant number: NUF-000600, SRC 019] and a János Bolyai Research Scholarship from the Hungarian Academy of Sciences.

The funders had no role in designing the study; collecting, analysing and interpreting the data; writing the report; deciding to submit the manuscript for publication.

Declaration of Competing Interest

Authors disclose no conflicts of interest.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.jcf.2020.12.008.

References

[1] Spoonhower KA, Davis PB. Epidemiology of cystic fibrosis. Clin Chest Med 2016;37(1):1–8.
[2] Elborn JS. Cystic fibrosis. Lancet 2016;388(10059):2519–31.
[3] Haller W, et al. Cystic fibrosis: an update for clinicians. Part 1: nutrition and gastrointestinal complications. J Gastroenterol Hepatol 2014;29(7):1344–55.
[4] Ledder O, et al. Cystic fibrosis: an update for clinicians. Part 2: hepato-biliary and pancreatic manifestations. J Gastroenterol Hepatol 2014;29(12):1954–62.
[5] Turck D, et al. ESPEN-ESPEN-ECTS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016;35(3):575–77.
[6] Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 2011;25(4):585–91.
[7] Martens PJ, et al. Vitamin D’s effect on immune function. Nutrients 2020;12(5).
[8] Tangpricha V, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012;97(4):1082–93.
[9] Ferguson JH, Chang AB. Vitamin D supplementation for cystic fibrosis. Cochrane Database Syst Rev 2014;4.
[10] Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
[11] Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Bountourioti I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:k4898.
[12] Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. Available from www.training.cochrane.org/handbook.
[13] Schünemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group; 2013. Available from guidelinerevelopment.org/handbook. When referring to a specific chapter or subsection refer to it by the title and section number, not page numbers. Example: Chapter authors in Schünemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE handbook for Grading quality of evidence and strength of recommendations. Version XX (updated XX 2014).
[14] GRADEpro GDT GRADEpro guideline development tool [Software]. McMaster University; 2020. (developed by Evidence Prime, Inc.). Available from grade-pro.org.
[15] Tangpricha V, et al. Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, placebo-controlled clinical trial. Am J Clin Nutr 2019;109(3):544–53.
[16] Pincikova T, et al. Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial. Eur J Clin Nutr 2017;71(2):203–5.
[17] Pincikova T, et al. Vitamin D treatment modulates immune activation in cystic fibrosis. Clin Exp Immunol 2017;189(3):359–71.
[18] Kauhner M, et al. Role of vitamin D on gut microbiota in cystic fibrosis. J Steroid Biochem Mol Biol 2018;175:82–7.
[19] Grossmann RE, et al. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: a randomized, controlled trial, Derma-to-endocrinology 2012;4(2):191–7.
[20] Grossmann RE, et al. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr 2012;66(9):1072–4.
[21] Hillman LS, et al. Percent true calcium absorption, mineral metabolism, and bone mineralization in children with cystic fibrosis: effect of supplementation with vitamin D and calcium. Pediatr Pulmonol 2008;43(8):772–80.
[22] Haworth CS, et al. Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. J Cyst Fibros 2004;3(4):233–6.
[23] Deghan Manshadi S, et al. A randomized placebo controlled trial of cholecalciferol for vitamin D deficiency in adults with cystic fibrosis. Pediatr Pulmonol 2012;47(Suppl 3):412. Abstract no: 515.
[24] Brown S, et al. Baseline BMD Status in children and young adults with CF: calcitriol intervention study: 460+ Pediatr Pulmonol 2005:40.
[25] Daley T, et al. Vitamin D deficiency and its treatment in cystic fibrosis. J Cyst Fibros 2019;18:566–73.
[26] van der Haak N, et al. Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand. J Cyst Fibros 2020;19(1):16–25.
[27] Institute of Medicine (US). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary Reference Intakes Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. 6, Tolerable Upper Intake Levels: Calcium and Vitamin D. Available from: https://www.nap.edu/catalog/11436.
[28] Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008;122(5):1142–52.
[29] Holick MF, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911–30.
[30] Cosman F, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. J. Established Result Cooperation Between Eur. Found. Osteoporosis Natl Osteoporosis Found USA 2014;25(10):2359–81.